Skip to Main Content
Skip Nav Destination

There is good evidence that targeting the beta cell could be an important component to developing the future of diabetes therapeutics. In this chapter, the authors review the principles of chemical biology that enable small-molecule discovery, the current state of the art for therapeutic approaches, novel beta cell-focused approaches to use small molecules that improve phenotypes, and more recent efforts to deliver therapeutics selectively to the beta cell.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal